36 DRUG DISCOVERY & DEVELOPMENT
Ethnobridging and the Asian market
Pharmaceutical studies must take into account cultural differences, as well as regulations that require the use of clinical data from native populations. Stanford Jhee reports.
Les études pharmaceutiques doivent tenir compte des différences culturelles ainsi que des réglementations qui nécessitent l’utilisation de données cliniques de la part des populations natives. Stanford Jhee fait son compte- rend.
Pharmazeutische Studien müssen kulturelle Unterschiede berücksichtigen sowie Regulierungen, die die Nutzung klinischer Daten einheimischer Bevölkerungen erfordern. Stanford Jhee berichtet.
F
inancial and competitive pressures mean that multinational
pharmaceutical companies are constantly looking for ways to make the drug development process more effective and efficient.
Te same pressures are inducing them to expand their efforts into wider international markets.
Focus shift According to IMS, Asia has the world’s highest rate of pharmaceutical sales growth, rising at an average annual rate of 15% between 2007 and 2012. Naturally, this is contributing to a shift in industry focus from Europe to Asia.
www.scientistlive.com
Japan is currently the world’s second largest pharmaceutical market, and is growing at a faster rate than the EU. Despite this, if projections by IMS hold true, China will overtake Japan by 2017 (currently it’s third after the US and Japan).
Similarly, it’s been suggested that clinical research in China for global drug development is increasing at an annual pace of 25%. In South Korea that figure’s even higher, at 30%. Such rapid growth is now presenting new opportunities and challenges for pharmaceutical organisations.
Sponsors of pharmaceutical studies must take into account cultural differences, as well
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92